# IN THE UNITED STATES DISTRICT COURT FILED DISTRICT OF MASSACHUSETTS

In re: LUPRON® MARKETING AND SALES PRACTICES LITIGATION	) 2004 OCT 29 ₱ 4: 22 ) MDL NO. 1430
THIS DOCUMENT RELATES TO	<ul> <li>り.S. DISTRICT COURT</li> <li>) Master File No. 015で配行る数 MASS.</li> <li>) 1:04-CV-10175-RGS</li> </ul>
CASE NO.: 1:04-CV-10175-RGS.	) Judge Richard G. Stearns

TAP PHARMACEUTICAL PRODUCTS INC.'S ANSWER AND AFFIRMATIVE DEFENSES TO COUNT V OF LIBERTY NATIONAL INSURANCE COMPANY AND UNITED AMERICAN INSURANCE COMPANY'S SECOND AMENDED COMPLAINT

Defendant, TAP Pharmaceutical Products Inc. ("TAP"), for its Answer and Affirmative

Defenses to Count V of Liberty National Insurance Company and United American Insurance

Company's Second Amended Complaint states as follows:

#### **COUNT FIVE**

## (Common Law Fraud) (Against Defendants Abbott and TAP)

153. Plaintiffs incorporate and reallege the previous paragraphs as if fully set forth herein.

ANSWER: TAP incorporates by reference Paragraphs 1 through 152 of TAP Pharmaceutical Products Inc.'s Answer and Affirmative Defenses to Second Amended Complaint Of Liberty National Insurance Company And United American Insurance Company, filed with this Court on March 12, 2004, as if fully set forth herein.

154. The Defendants' misrepresentations and/or omissions discussed herein were knowingly false, misleading, and/or fraudulent or were made with reckless indifference to the truth.

<u>ANSWER</u>: To the extent the allegations in Paragraph 154 constitute legal conclusions, no response is required. TAP denies the remaining allegations in Paragraph 154.

155. In overstating the AWP for Lupron<sup>®</sup>, the defendants caused such representations to be made with the intent of inducing the public, including Liberty National and United American, to act upon them and overpay for the drug.

#### ANSWER: Denied.

156. The misrepresentations and omissions were material to the amounts Liberty National and United American reimbursed for prescriptions of Lupron<sup>®</sup>, and were made in order to induce Liberty National and United American to make higher payments.

**ANSWER**: To the extent the allegations in Paragraph 156 constitute legal conclusions, no response is required. TAP denies the remaining allegations in Paragraph 156.

157. Liberty National and United American reasonably relied on the misrepresentations or omissions made by or on behalf of the Defendants, including but not limited to those representations made regarding the AWP in the pharmaceutical industry publication, *Red Book*.

**ANSWER**: To the extent the allegations in Paragraph 157 constitute legal conclusions, no response is required. TAP denies the remaining allegations in Paragraph 157.

158. But for the Defendants' material misrepresentations and omissions, Liberty National and United American would not have overpaid for Lupron<sup>®</sup>, and would not have suffered the financial loss arising from Defendants' deceptive schemes.

#### **ANSWER**: Denied.

159. By reason of the foregoing, and as a proximate cause of said fraud and acts committed in furtherance thereof, Liberty National and United American have suffered grievous injury and has been damaged as alleged herein.

**ANSWER**: To the extent the allegations in Paragraph 159 constitute legal conclusions, no response is required. TAP denies the remaining allegations in Paragraph 159.

160. The acts alleged were malicious, oppressive, and contrived for the purpose of achieving the objects of the fraud; therefore, Liberty National and United American are entitled to punitive damages.

ANSWER: To the extent the allegations in Paragraph 160 constitute legal conclusions, no response is required. TAP denies the remaining allegations in Paragraph 160.

CHI-1440756v1 -2-

#### **AFFIRMATIVE DEFENSES**

TAP incorporates by reference its Affirmative Defenses listed in TAP Pharmaceutical Products Inc.'s Answer and Affirmative Defenses to Second Amended Complaint Of Liberty National Insurance Company And United American Insurance Company, filed with this Court on March 12, 2004, as if fully set forth herein.

Dated: October 29, 2004

Joseph F. Savage, Jr.
TESTA, HURWITZ & THIBEAULT

High Street Tower 125 High Street Boston, MA 02110 (617) 248-7000

(617) 248-7100 (facsimile)

Daniel E. Reidy
Irene Savanis Fiorentinos
Tina M. Tabacchi
JONES DAY
77 West Wacker Drive
Chicago, Illinois 60601-1692
(312) 782-3939
(312) 782-8585 (facsimile)

ATTORNEYS FOR TAP PHARMACEUTICAL PRODUCTS INC.

CHI-1440756v1 -3-

### **CERTIFICATE OF SERVICE**

The undersigned attorney certifies that on the 29th day of October 2004 the foregoing TAP Pharmaceutical Products Inc.'s Answer and Affirmative Defenses to Count V Of Liberty National Insurance Company and United American Insurance Company's Second Amended Complaint was served, by first class mail, postage prepaid, to:

Charles A. Dauphin
Donald R. James, Jr.
Joseph D. Jackson, Jr., Esq.
BAXLEY, DILLARD, DAUPHIN, MCKNIGHT & BARCLIFT
2008 3<sup>rd</sup> Avenue South
Birmingham, Alabama 35233

Thomas M. Sobol HAGENS BERMAN LLP One Main Street Fouth Floor Cambridge, MA 02142

Anita B. Ban